Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex—bound immunogenic peptides induced by interferon-α and interferon-γ treatment of human glioblastoma multiforme

Yang, Isaac; Kremen, Thomas J.; Giovannone, Adrian J.; Paik, Elena; Odesa, Sylvia K.; Prins, Robert M.; Liau, Linda M.

doi:10.3171/jns.2004.100.2.0310

Cited by 76 publications

(54 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fluorescence-activated cell sorting analysis and immunohistochemistry for MHC class I was done on the glioblastoma multiforme cell lines and all expressed MHC class I molecules, although at variable levels. Exposing cell cultures to IFN-g and IFN-a up-regulated both MHC class I expression and the amount of glioblastomaassociated peptides harvested by acid elution, suggesting that the acid-eluted material was indeed associated with MHC molecules (28). Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of the acid-eluted material revealed molecular weights between 800 and 1500 daltons, which were compatible with the size of peptides (9-12 amino acids) accommodated by the peptide-binding cleft of MHC alleles.…”

Section: Resultsmentioning

confidence: 99%

“…Fresh tumor samples from surgical resection were transported under sterile conditions to the UCLA Jonsson Cancer Center GMP facility and used to establish autologous primary glioblastoma multiforme cell lines, as previously described (27,28). Cultured tumor cells were harvested and used for acid elution of surface peptides.…”

Section: Methodsmentioning

confidence: 99%

“…Peptide washes were then lyophilized to complete dryness, resuspended in 0.2 mL dPBS, aliquoted, and frozen at À80jC. A 5-AL sample of each peptide preparation was quantified by microprotein assay (Bio-Rad, Hercules, CA) and analyzed by matrix-assisted laser desorption/ionization timeof-flight mass spectrometry (Bruker Daltonics, Billerica, MA) as previously published (28). Before patient vaccination, tumor peptides were also tested for sterility by Gram stain; Limulus amebocyte lysate assay (Bio Whittaker, Walkersville, MD); and routine aerobic, anaerobic, and fungal cultures.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

Liau

Prins²,

Kiertscher

et al. 2005

Clinical Cancer Research

Self Cite

471

359

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

Liau

Prins²,

Kiertscher

et al. 2005

Clinical Cancer Research

Self Cite

471

359

View full text Add to dashboard Cite

show abstract

“…The biological activities of type I IFNs include growth inhibition of tumor cells, 16,17 induction of apoptosis, 17,18 natural killer cell activation, 19 and an increase in the expression of major histocompatibility complex (MHC) class I molecules. 20,21 The amino acid sequence of recombinant feline IFN-v has approximately 60% homology to that of human IFN-v. 22 The antitumor efficacy of human IFN-v has been described in vitro 23,24 and in vivo. 25 Recombinant feline IFN-v has approximately 60% homology to human IFN-a.…”

mentioning

confidence: 99%

“…21 32,34 To assess the biological effect of rFeIFN-v on MHC class I and II expression on feline fibrosarcoma cells, flow cytometry from 5 unrelated fibrosarcoma cell lines was carried out. The effect of rFeIFN-v was compared with that of rFeIFN-c. RFeIFN-v was administered to domestic cats before and after tumor excision.…”

mentioning

confidence: 99%

Adjuvant Immunotherapy of Feline Fibrosarcoma with Recombinant Feline Interferon-ω

Hampel¹,

Schwarz

Kempf

et al. 2007

J Vet Int Med

View full text Add to dashboard Cite

Background: Recombinant feline interferon-v (rFeIFN-v) was tested as a treatment option for cats with fibrosarcoma to assess safety and feasibility.Hypothesis: Treatment with rFeIFN-v in cats with fibrosarcoma is safe and feasible. Animals: Twenty domestic cats. Methods:In an open-labeled uncontrolled clinical trial 12 injections of 1 3 10 6 U/kg rFeIFN-v were administered over a 5-week period: the 1st through 4th injections were given intratumorally, and the 5th through 12th injections were administered subcutaneously at the tumor excision site. Wide surgical excision of the tumors was carried out after the 4th injection and before the 5th injection of rFeIFN-v. A Common Terminology Criteria for Adverse Events (CTCAE) analysis was conducted. Flow cytometry of fibrosarcoma cells after incubation with rFeIFN-v and recombinant feline interferon-c was performed to assess the biological effect of rFeIFN-v.Results: Changes in blood cell count, increases in serum aspartate-amino-transferase activity, serum bilirubin concentration, serum creatinine and serum electrolyte concentrations, weight loss, anorexia, increased body temperature, and reduced general condition were observed but were mostly minor (grade 1 and 2) and self limiting. Eosinophilia (P 5 .025), neutropenia (P 5 .021), and weight loss (P , .001) were statistically correlated with rFeIFN-v-treatment (analysis of parameters before treatment and after 3 injections of rFeIFN-v). Flow cytometry of 5 unrelated feline fibrosarcoma cell lines showed increased expression of major histocompatibility complex (MHC) class I molecules (P 5 .026) in response to in vitro incubation with rFeIFN-v, whereas expression of MHC class II molecules was not affected significantly.Conclusions and Clinical Importance: RFeIFN-v for the treatment of feline fibrosarcoma is safe, well tolerated, and can be easily performed in practice. To assess the efficacy of the treatment, it should be tested in a placebo-controlled trial.

show abstract

Viral Pathogenesis, Modulation of Immune Receptor Signaling and Treatment

Kim

Sigalov

2008

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

During the co-evolution of viruses and their hosts, the latter have equipped themselves with an elaborate immune system to defend themselves from the invading viruses. In order to establish a successful infection, replicate and persist in the host, viruses have evolved numerous strategies to counter and evade host antiviral immune responses as well as exploit them for productive viral replication. These strategies include those that target immune receptor transmembrane signaling. Uncovering the exact molecular mechanisms underlying these critical points in viral pathogenesis will not only help us understand strategies used by viruses to escape from the host immune surveillance but also reveal new therapeutic targets for antiviral as well as immunomodulatory therapy. In this chapter, based on our current understanding of transmembrane signal transduction mediated by multichain immune recognition receptors (MIRRs) and the results of sequence analysis, we discuss the MIRR-targetingviral strategies of immune evasion and suggest their possible mechanisms that, in turn, reveal new points of antiviral intervention. We also show how two unrelated enveloped viruses, human immunodeficiency virus and human cytomegalovirus, use a similar mechanism to modulate the host immune response mediated by two functionally different MIRRs-T-cell antigen receptor and natural killer cell receptor, NKp30. This suggests that it is very likely that similar general mechanisms can be or are used by other viral and possibly nonviral pathogens.

show abstract

Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex—bound immunogenic peptides induced by interferon-α and interferon-γ treatment of human glioblastoma multiforme

Cited by 76 publications

References 43 publications

Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

Adjuvant Immunotherapy of Feline Fibrosarcoma with Recombinant Feline Interferon-ω

Viral Pathogenesis, Modulation of Immune Receptor Signaling and Treatment

Contact Info

Product

Resources

About